GENMAB A/S |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 268.9 EUR | -0.11% |
|
-0.66% | -6.69% |
| May. 21 | Genmab A/S completed the acquisition of ProfoundBio, Inc. | CI |
| May. 15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.8B 2.88B 2.65B | Sales 2025 * | 23.62B 3.44B 3.16B | Capitalization | 129B 18.81B 17.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.67B 680M 626M | Net income 2025 * | 6.61B 962M 885M | EV / Sales 2024 * | 5.26 x |
| Net cash position 2024 * | 25.1B 3.65B 3.36B | Net cash position 2025 * | 32.35B 4.71B 4.33B | EV / Sales 2025 * | 4.1 x |
| P/E ratio 2024 * |
29.5
x | P/E ratio 2025 * |
21.2
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 week | -0.66% | ||
| Current month | +3.38% | ||
| 1 month | +0.60% | ||
| 3 months | +0.90% | ||
| 6 months | -5.34% | ||
| Current year | -6.69% |
1 week
268.90
278.70
1 month
257.10278.70
3 years
245.30448.50
5 years
145.95448.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
| Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 268.9 | -0.11% |
| 24-05-21 | 269.2 | -1.97% |
| 24-05-20 | 274.6 | +0.15% |
| 24-05-17 | 274.2 | +0.07% |
| 24-05-16 | 274 | -1.33% |
Real-time BOERSE MUENCHEN, May 22, 2024 at 04:13 am EDT
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
2,002
DKK
Average target price
2,466
DKK
Spread / Average Target
+23.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -2.47% | 21.28B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B | |
| -28.60% | 7.83B |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock